These effects appear to be mediated by the activation of hepatic AMPK and AKT signaling, thereby uncovering a mechanistic basis for zinc-induced liver protection and indicating that SLC39A5 inhibition may hold therapeutic potential in NAFLD and T2D (Figure 1—figure supplement 1). The gene discussed is SLC39A5; the disease is type 2 diabetes mellitus.